Minnesota is currently home to 2063 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
NCT06014541
Recruiting
The purpose of the study is to prospectively assess longitudinal changes in biomarkers (MECP2, potential biomarkers of target engagement and disease activity) in cerebrospinal fluid (CSF) and blood; characterize longitudinal changes in performance on clinical scales (clinician-reported measures of neurodevelopment and functioning) and caregiver-reported outcome assessments (communication, gastrointestinal, social-emotional-adaptive behavioral measures); evaluate longitudinal changes in caregiver... Read More
Gender:
MALE
Ages:
Between 1 month and 65 years
Trial Updated:
02/03/2025
Locations: Gillette Children's Specialty Healthcare, Saint Paul, Minnesota
Conditions: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Minneapolis Heart Institute, Minneapolis, Minnesota
Conditions: Coronary Artery Disease
Register for Updates
Gait Adaptation and Biofeedback for Cerebral Palsy
NCT05899153
Recruiting
This research aims to evaluate walking function in children with cerebral palsy (CP). The researchers want to understand how children with CP adapt and learn new ways of moving. They have previously found that measuring how a person controls their muscles is important for assessing walking ability and response to interventions. In these studies, they will adjust the treadmill belt speeds and/or provide real-time feedback to evaluate how a child can alter their movement. The feedback will include... Read More
Gender:
ALL
Ages:
Between 7 years and 18 years
Trial Updated:
02/03/2025
Locations: Gillette Children's, Saint Paul, Minnesota
Conditions: Cerebral Palsy
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Minnesota Oncology Hematology, P.A, Woodbury, Minnesota
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
Statins for the Treatment of NASH
NCT04679376
Recruiting
The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor®), is safe and effective in improving the features of NASH.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/03/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Shared Decision Making to Improve Goals of Care in the ED
NCT03833622
Recruiting
This project will develop and refine a shared decision making (SDM) intervention (decision aid tool) to improve and normalize high quality end of life discussions in the Emergency Department (ED) setting.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/03/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Goals
Register for Updates
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
NCT03314974
Recruiting
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).
Gender:
ALL
Ages:
60 years and below
Trial Updated:
02/03/2025
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
Register for Updates
MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)
NCT05586243
Recruiting
Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stable therapy. However, alterations in neurometabolites in adult patients with GD3, who have established neurological involvement, are not well understood. The goal of this study is to characterize neurometabolite profiles in adult patients with GD3 using MRS to identify novel biomarkers that can demonstrate treatment response. Additionally,... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/02/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Gaucher Disease, Type 3
Register for Updates
Phenotype-Tailored Lifestyle Intervention for Obesity: a Randomized Trial
NCT06770049
Recruiting
The purpose of this study is to develop an evidence-based precision medicine approach for obesity that enhances weight loss and promotes weight loss maintenance.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Obesity
Register for Updates
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
NCT06374459
Recruiting
This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Register for Updates
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386
Recruiting
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.
Gender:
ALL
Ages:
Between 12 years and 60 years
Trial Updated:
01/31/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: IC-MPGN
Register for Updates
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
NCT04889430
Recruiting
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/31/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Atypical Hemolytic Uremic Syndrome
Register for Updates